HIS
ESPR

Harvest Investment Services’s Esperion Therapeutics ESPR Stock Holding History

Harvest Investment Services’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-15,736
Closed -$105K – 124
2022
Q3 		$105K Buy
+15,736
New +$108K 0.13% 106

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Harvest Investment Services's ESPR Position: Q4 2022 in Review

Harvest Investment Services sold out of Esperion Therapeutics (ESPR) in Q4 2022, closing a stake of 15,736 shares — an estimated $105K sold.

Harvest Investment Services first reported a position in ESPR in Q3 2022 and held it in 1 quarter. The position peaked at $105K in Q3 2022. 165 funds tracked by Wall St. Rank hold ESPR as of Q4 2022.

  • Harvest Investment Services reported no remaining Esperion Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Harvest Investment Services sold 15,736 Esperion Therapeutics shares in Q4 2022, an estimated $105K.
  • Harvest Investment Services first reported a position in Esperion Therapeutics in Q3 2022 and held it in 1 quarter.
  • Harvest Investment Services's Esperion Therapeutics position peaked at $105K in Q3 2022.
  • 165 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2022.

Based on Harvest Investment Services's 13F filing for Q4 2022, filed 14 Feb 2023.